United StatesEli Lilly has released new data on its next-generation obesity drug, retatrutide, which showed significant weight loss among patients with severe obesity and heart disease. However, the study did not provide conclusive evidence on whether the drug reduces cardiovascular risks, such as heart attacks or strokes. The Phase 3 trial involved nearly 2,000 participants, with those receiving the highest dose losing 22.6% of their body weight over 80 weeks compared to 3.2% for those on a placebo. While the drug demonstrated efficacy in weight loss, the trial was not designed to assess cardiovascular outcomes, and the number of heart-related events observed was lower than expected, making it difficult to determine the drug's impact on cardiovascular health.
Bias read (Center): The article presents findings from a clinical trial regarding a pharmaceutical product without overtly favoring any political perspective. It discusses the drug's efficacy in weight loss and acknowledges limitations in assessing cardiovascular benefits, maintaining a balanced tone without apparent倾向
